Pyxis Oncology, Inc. (PYXS) Stock Forecast
PYXS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.70 / 5 from 10 analysts
- Price target
- $8.67 average of analyst targets
- Upside to target
- +415.9% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $-0.27
- 52-week range
- $1.06 – $5.34
PYXS analyst ratings
10 analystsNumber of analysts at each rating.
PYXS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PYXS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.28 | −$0.36 | −$0.22 | −$0.35 | +20.6% | 9 |
| Current fiscal year (2026) | −$1.21 | −$1.49 | −$0.99 | −$1.28 | +5.2% | 9 |
| Next fiscal year (2027) | −$1.11 | −$1.70 | −$0.73 | −$1.21 | +8.7% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PYXS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $19,440 | $0 | $175,000 | −99.9% | 9 |
| Next fiscal year (2027) | $2.8M | $0 | $25.0M | +14,189.0% | 9 |
PYXS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PYXS revenue: reported and forecast
PYXS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.28 | −$0.28 | −$0.28 | −$0.28 | −$0.28 | +1.0% | 4 up · 3 down |
| Current fiscal year (2026) | −$1.22 | −$1.22 | −$1.22 | −$1.22 | −$1.21 | −0.9% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.21 | −$1.20 | −$1.13 | −$1.13 | −$1.11 | −8.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PYXS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PYXS beat in 5 of 12.
What analysts expect from PYXS
10 analysts cover Pyxis Oncology; their consensus rating is strong buy (4.70 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.67, 415.9% above the latest close of $1.68. Analysts expect earnings of −$1.21 per share for 2026, +5.2% from a year earlier. For 2027 the average estimate is −$1.11 per share on revenue of $2.8 million. Pyxis Oncology beat the EPS estimate in 5 of the last 12 quarters.
Related: PYXS income statement, PYXS key metrics, PYXS chart. See the PYXS stock overview for the latest quote and news.
PYXS forecast FAQ
What is Pyxis Oncology's price target?
The average analyst price target for Pyxis Oncology is $8.67, 415.9% above the latest close of $1.68.
Is Pyxis Oncology a buy, hold or sell?
Of 10 analysts covering Pyxis Oncology, 8 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Pyxis Oncology's EPS forecast?
Analysts forecast −$1.21 per share for 2026 (range −$1.49 to −$0.99); for 2027 the estimate is −$1.11.
What is Pyxis Oncology's revenue forecast?
The average revenue estimate for 2026 is $0.0 million, growth of −99.9%; for 2027 it is $2.8 million.
When does Pyxis Oncology report earnings?
Pyxis Oncology is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 before the market opens; the EPS estimate is $-0.27.
Does Pyxis Oncology usually beat earnings estimates?
Pyxis Oncology reported EPS at or above the analyst estimate in 5 of the last 12 quarters.